文献速递淋巴瘤

慢性淋巴细胞白血病:2020年诊断、风险分层与治疗更新

Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment.
PubMed 文献 · Am J Hematol · 2019-10-04

该综述总结了慢性淋巴细胞白血病(CLL)的诊断、预后与治疗进展。诊断基于血常规、血涂片及流式免疫表型鉴定克隆性B细胞。Rai和Binet分期及生物学标志物提供预后信息,del(17p)/TP53突变提示对 chemoimmunotherapy 耐药。治疗仅适用于有症状或晚期患者,选项包括venetoclax联合obinutuzumab、ibrutinib单药或 chemoimmunotherapy;高危患者应使用靶向药物,合适者考虑异基因移植。

要点

  • 诊断依赖血常规、血涂片和流式免疫表型确认CD5阳性克隆性B细胞。
  • del(17p)或TP53突变提示对 chemoimmunotherapy 耐药且进展快,应选用靶向药物。
  • 仅活动性、症状性或晚期(Binet/Rai)CLL患者需治疗,优选临床试验。

核心结论

  • CLL诊断基于血常规、血涂片和流式免疫表型鉴定CD5阳性克隆性B细胞。
  • del(17p)或TP53突变提示对 chemoimmunotherapy 耐药且无进展生存缩短,多数靶向治疗亦如此。
  • 仅活动性、症状性或晚期Binet/Rai分期患者需治疗;高危患者应使用靶向药物,合适者考虑异基因移植。

研究设计与样本

  • 综述,纳入CLL诊断、风险分层与治疗相关文献。

主要发现

  • Rai和Binet两个相似临床分期系统利用体格检查和血常规结果提供预后信息。
  • 多种生物学和遗传学标志物也有预后价值。
  • CLL-IPI综合遗传、生物学和临床变量识别不同风险组。

关键数值与推荐

  • 适合的65岁以下、尤其IGVH突变患者,氟达拉滨+环磷酰胺+利妥昔单抗 chemoimmunotherapy 仍是标准治疗,可能具治愈潜力。
  • 复发时若无治疗间期超过3年可重复初始治疗;否则应换用替代方案。
  • del(17p)或TP53突变患者属高危,应接受靶向药物治疗。
  • 复发伴TP53突变或del(17p)、或对抑制剂治疗难治者,可考虑异基因造血干细胞移植。

临床怎么用

  • 治疗前评估疾病活动性、Binet/Rai分期及del(17p)/TP53状态。
  • 高危(del(17p)/TP53突变)患者优先选用靶向药物。
  • 复发时根据无治疗间期决定重复或更换方案。
  • 尽可能在临床试验中治疗CLL患者。

局限性

  • 靶向药物联合方案能否优于BTK抑制剂单药的长效缓解尚待证实。
  • 药物联合的最佳序贯顺序未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Chronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries. The disease typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that impair apoptosis of clonal B-cells. DIAGNOSIS: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B-lymphocytes, which identify a clonal B-cell population carrying the CD5 antigen, as well as typical B-cell markers. PROGNOSIS: The two similar clinical staging systems, Rai and Binet, create prognostic information by using results of physical examination and blood counts. Various biological and genetic markers also have prognostic value. Deletions of the short arm of chromosome 17 (del [17p]) and/or mutations of the TP53 gene, predict resistance to chemoimmunotherapy and a shorter time to progression, with most targeted therapies. A comprehensive, international prognostic score (CLL-IPI) integrates genetic, biological and clinical variables to identify distinct risk groups of CLL patients. THERAPY: Only patients with active or symptomatic disease, or with advanced Binet or Rai stages require therapy. When treatment is indicated, several options exist for most CLL patients: a combination of venetoclax with obinutuzumab, ibrutinib monotherapy, or chemoimmunotherapy. For physically fit patients younger than 65 (in particular when presenting with a mutated IGVH gene), chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab remains a standard therapy, since it may have curative potential. At relapse, the initial treatment may be repeated, if the treatment-free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del (17p) or TP53 mutation are a different, high-risk category and should be treated with targeted agents. An allogeneic SCT may be considered in relapsing patients with TP53 mutations or del (17p), or patients that are refractory to inhibitor therapy. FUTURE CHALLENGES: Targeted agents (ibrutinib, idelalisib, venetoclax, obinutuzumab) will be increasingly used in combination to allow for short, but potentially definitive therapies of CLL. It remains to be proven that they generate a superior outcome when compared to monotherapies with inhibitors of Bruton tyrosine kinase, which can also yield long-lasting remissions. Moreover, the optimal sequencing of drug combinations is unknown. Therefore, CLL patients should be treated in clinical trials whenever possible.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019. PMID: 31364186. doi:10.1002/ajh.25595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。